Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $5.17.

Several equities research analysts have recently weighed in on the company. Truist Financial decreased their price target on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Royal Bank of Canada reiterated a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, April 7th.

Sangamo Therapeutics Trading Down 1.7 %

SGMO opened at $0.73 on Monday. The company has a 50 day moving average of $0.81 and a 200 day moving average of $1.38. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The company has a market cap of $166.92 million, a PE ratio of -0.97 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The company had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. Research analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several hedge funds have recently added to or reduced their stakes in SGMO. Geode Capital Management LLC raised its holdings in shares of Sangamo Therapeutics by 14.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock valued at $1,853,000 after buying an additional 272,123 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Sangamo Therapeutics during the third quarter worth approximately $150,000. Shelton Wealth Management LLC bought a new stake in shares of Sangamo Therapeutics in the 4th quarter worth approximately $29,000. Golden State Equity Partners boosted its stake in shares of Sangamo Therapeutics by 2,592.3% in the 4th quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock valued at $332,000 after purchasing an additional 313,587 shares in the last quarter. Finally, Sageworth Trust Co bought a new position in shares of Sangamo Therapeutics during the 4th quarter valued at $61,000. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.